Researchers assessed whether depression in the presence or absence of previous GI symptoms is associated with a future diagnosis of IBD.
Investigators evaluated the association between regular proton pump inhibitor use and the risk for inflammatory bowel disease and its subtypes.
Investigators analyzed the association between consumption of ultra-processed foods and risk for Crohn disease and ulcerative colitis.
Authors assessed the safety and efficacy of current methods for managing abdominal pain in patients with ulcerative colitis.
The application is supported by data from two phase 3 induction studies (ADVANCE and MOTIVATE) and one phase 3 maintenance study (FORTIFY).
The global prevalence of primary sclerosing cholangitis ranges from 0.96 percent in Crohn disease to 2.47 percent in ulcerative colitis.
Investigators assessed whether increased antibody responses to microbial antigens is an independent risk factor for future development of Crohn disease.
Researchers described the evolution of dietary patterns and the outcomes they have on the gut microbiome, immune function, and inflammation in people with IBD.
One key factor that has developed increasing research interest is the role of a patient’s BMI, specifically those with obesity (BMI > 30 kg/m2), in the development of IBD.
Investigators reviewed the current clinical presentations and treatment options for extraintestinal manifestations in patients with inflammatory bowel disease.
Researchers assessed the practices favored by pediatric gastroenterologists for combination immunosuppression in patients with pediatric inflammatory bowel disease.
Investigators performed a retrospective analysis to compare COVID-19 vaccine outcomes in patients with IBD against those without.
Investigators assessed trends in corticosteroid use in patients with IBD over a period of 20 years.
Researchers evaluated whether higher empirical dietary inflammatory pattern scores were associated with increased risk of developing IBD.
Investigators attempted to define the role of interleukin-2-inducible T-cell kinase activation in ulcerative colitis.
Investigators conducted an open-label extension to evaluate the long-term safety and efficacy of risankizumab for the treatment of moderate to severe Crohn disease.
Investigators aimed to evaluate and update the Lémann index for the assessment of cumulative bowel damage in patients with Crohn disease.
Due to the relatively high relapse rate and need for additional therapies, current research is being done on the use of Vedolizumab for the treatment of microscopic colitis.
Investigators performed a systematic review to examine the varying definitions of transmural healing and assess its impact on CD-related outcomes.
Researchers compared the effectiveness of the specific carbohydrate diet with the Mediterranean diet for the management of Crohn disease symptoms.